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Abstract Disclosures
Background:
The presence of BM in AGC is a relatively uncommon finding and has a poor prognosis [Leporini C. 2015]. At diagnosis the presence of BM 
occurs in approximately 10-15% of pts with AGC.[Park 2011; Silvestris 2013]. Aim of this study is to describe the main features of pts with 
AGC and BM at diagnosis and the prognostic implications. 
Methods:
A consecutive series of AGC followed at Cremona Oncology Division from November 2004 to Dicember 2016 and included in three 
consecutive prospective trials [Dalla Chiesa M. 2011; Tomasello G. 2013], were analyzed. All pts were treated with a modified DCF (docetaxel, 
cisplatin, fluorouracil) given as a dose-dense regimen, every 14 days. We analyzed pts with BM at diagnosis (BMaD) and pts without BMaD. 
We evaluated baseline clinical and pathological parameters, the presence of coagulation disorders (CD) together with efficacy measures in 
the two groups. 
Results:
218 pts with AGC were identified (38 with BMaD and 180 without BMaD).Main pts characteristics and results are reported in the Table below. 
Conclusions:
The presence of BM at diagnosis in pts with AGC is not a rare event (21%) and identifies a population with a significantly poorer outcome and 
a higher incidence of CD, that need a clinical monitoring of coagulation parameters. More efforts are required to understand the reasons of 
the different prognosis and to find specific treatments to improve the survival. 
Pts characteristics and results.
Parameter No BM (N=180) BM (N=38) P value
Age, median 65 62 0.2
Sex: M/F (%) 73/27 81/19 0.29
PS 0-1-2 (%) 52-42-6 42-37-18 0.11
Mets sites >2 29/180 (16%) 26/36 (72%) 0.01
DCR 81% 63% 0.002
PFS, median (95%IC) 7.8 (6.7-9.3) 5.2 (2.5-7.1) <0.001
OS median (95%IC) 13.1 (10.9-15) 7.0 (5.8-9.0) <0.001
CD 1/180 (0.6%)* 7/28 (25%)** <0.001
DCR: Disease Control Rate. OS: Overall Survival; PFS: Progression Free Survival. Coagulation Disorders (CD) = *DIC Disseminated 
Intravascular Coagulation 1 pt; **DIC 5 pts, Thrombotic Thrombocytopenic Purpura 1pt, and Moskowitz Syndrome 1 pt
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